Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Demonstrates Efficacy Of Pitavastatin In Elderly Patients
New data presented showed that pitavastatin is an effective treatment for the management of dyslipidemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin. The Phase III data were presented by Kowa, at the XV International Symposium on Atherosclerosis in Boston.

Link Between Specific Antibodies And Spina Bifida Ruled Out By Irish-Led Research Team
New research, publishedin the New England Journal of Medicine, shows that a woman"s risk of having a child with a neural tube defect (NTD), such as Spina Bifida, is not linked to folic acid related auto-antibodies. The findings refute a well publicised study in 2004, which had indicated a link between the presence of these auto-antibodies in the circulation of mothers who had children with Spina Bifida compared to those who did not.
News of the day
The Countdown Starts For Pharmacy Technician Registration
Pharmacy technicians throughout England, Scotland and Wales will be regulated by the Royal
Oncology

Meridian Bioscience Receives FDA Clearance For New Rapid Campylobacter Test

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United States. Approximately 20 million stool culture tests are conducted each year in the U.S. to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact. There is a real need for the ImmunoCard STAT!® CAMPY because of its simplified, easy to perform procedure that provides patient results in 20 minutes. In addition, ImmunoCard STAT!® CAMPY provides a solution to several concerns associated with culture testing, currently the most commonly practiced lab technique for detecting the Campylobacter bacteria. With culture, there is a potential for reduction in sensitivity due to variable culturing procedures, specimen viability, and inhibitory antibiotics in culture media. ImmunoCard STAT!® CAMPY dramatically reduces these concerns with a consistent method that measures the bacterial antigen instead of measuring the viability of this fragile bacteria in an environment that is less inhibitory than current culturing procedures. John A. Kraeutler, Chief Executive Officer, stated, "ImmunoCard STAT!® CAMPY is a significant addition to our foodborne category because it provides laboratories with a rapid, accurate and easy to perform platform for the detection of Campylobacter. This innovative assay, along with Meridian"s Premier™ CAMPY and toxigenic E. coli tests, demonstrates Meridian"s emerging leadership in foodborne testing. ImmunoCard STAT!® CAMPY is already in distribution by Meridian Bioscience Europe for the Company"s European markets and was also recently approved for sale in Canada." Meridian Bioscience, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009